Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA drug recalls in 2018

Every FDA drug recall initiated in 2018, newest first, with its risk class, status and the reason the FDA recorded. Use the cause and risk filters to narrow the year down.

1,681 recalls, newest first.

Class II · Moderate risk

Ethosuximide Capsules

Failed Impurities/Degradation Specifications: Out of specification (OOS) results for unspecified impurity.

Terminated Impurity / degradation Akorn, Inc. D-1183-2018
Class II · Moderate risk

Thyroid Powder

CGMP Deviations: Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.

Terminated cGMP deviation LGM Pharma LLC D-0296-2019
Class II · Moderate risk

Cortaid 12-Hour Advanced Anti-itch Cream

CGMP deviations: Notice received from supplier of a voluntary recall of all their nasal products and baby oral gels due to the possibility of microbial contamination. No positive results for the firm's products. were obtained. After the firm review, cGMP deviations ere evident.

Terminated Microbial contamination Valeant Pharmaceuticals North America LLC D-0086-2019
Class II · Moderate risk

Cortaid Maximum Strength Cream

CGMP deviations: Notice received from supplier of a voluntary recall of all their nasal products and baby oral gels due to the possibility of microbial contamination. No positive results for the firm's products. were obtained. After the firm review, cGMP deviations ere evident.

Terminated Microbial contamination Valeant Pharmaceuticals North America LLC D-0085-2019
Class II · Moderate risk

Cortaid Intensive Therapy Cooling Spray

CGMP deviations: Notice received from supplier of a voluntary recall of all their nasal products and baby oral gels due to the possibility of microbial contamination. No positive results for the firm's products. were obtained. After the firm review, cGMP deviations ere evident.

Terminated Microbial contamination Valeant Pharmaceuticals North America LLC D-0084-2019
Class III · Low risk

Morphine Sulfate Extended-Release Tablets

Failed Impurities/Degradation Specifications: Morphine Sulfate Extended Release Tablets are being recalled due to out of Specification Result noticed for Morphinone Sulfate impurity during 3 month stability analysis and during retain testing.

Terminated Impurity / degradation Lupin Somerset NDC 43386-541-01 D-1214-2018
Class I · High risk

Respitrol

Microbial Contamination of Non Sterile Products; Products contaminated with microoganisms, including but not limited to Staphylococcus saprophyticus and Burkholderia cepacia

Terminated Microbial contamination Hellolife D-1203-2018
Class I · High risk

Thyroveev

Microbial Contamination of Non Sterile Products; Products contaminated with microoganisms, including but not limited to Staphylococcus saprophyticus and Burkholderia cepacia

Terminated Microbial contamination Hellolife D-1202-2018
Class I · High risk

Neuroveen

Microbial Contamination of Non Sterile Products; Products contaminated with microoganisms, including but not limited to Staphylococcus saprophyticus and Burkholderia cepacia

Terminated Microbial contamination Hellolife D-1201-2018
Class I · High risk

Compulsin

Microbial Contamination of Non Sterile Products; Products contaminated with microoganisms, including but not limited to Staphylococcus saprophyticus and Burkholderia cepacia

Terminated Microbial contamination Hellolife D-1200-2018
Class II · Moderate risk

Cefuroxime 10mg/mL INJ 0.5 mg

Presence of Particulate Matter: Particulate matter was reported in one lot of Cefuroxime by a physician after use of product.. FDA analysis identified the particulate as coring of the rubber stopper

Terminated Particulate / foreign matter Pacific Compounding Pharmacy & Consultations Inc D-1076-2019
Class II · Moderate risk

Thyroid Powder USP

CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.

Terminated cGMP deviation Syntec Pharma Corp D-0014-2019
Class II · Moderate risk

Thyroid Powder USP

CGMP Deviations: Recall notice received from supplier that Thyroid Powder has inconsistent levels of the active ingredients levothyroxine and liothyronine.

Terminated cGMP deviation Syntec Pharma Corp D-0013-2019
Class I · High risk

Hydrochlorothiazide Tablets USP

Product Mix-Up: customer complaint that a sealed bottle labeled as Hydrochlorothiazide Tablets USP 12.5 mg contained only Spironolactone Tablets USP 25 mg.

Terminated Labeling / mix-up Accord Healthcare, Inc. NDC 16729-182-01 D-1206-2018
Class II · Moderate risk

Methyl-Cobalamin injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1167-2018
Class II · Moderate risk

Folic Acid injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1166-2018
Class II · Moderate risk

Methyl-Cobalamin injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1162-2018
Class II · Moderate risk

Methyl-Cobalamin injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1161-2018
Class II · Moderate risk

Methyl-Cobalamin injectable

Lack of Assurance of Sterility: Inadequate processes and equipment to assure the sterility of products intended to be sterile.

Terminated Sterility / contamination Auro Pharmacies, Inc. D-1160-2018

Recalls by year